Limited expression of B-cell maturation antigen in acute myeloid leukemia
Research prevents pursuit of an ineffective CAR-T cell approach in leukemia, protecting patients from unnecessary experimental toxicity.
This study refutes recent claims that BCMA is a viable CAR-T target in AML, demonstrating that the commonly-used antibody clone (19F2) produces false-positive BCMA detection via Fc-mediated non-specific binding. Anti-BCMA CAR-T cells showed minimal leukemic cell killing, warning against premature clinical development of this approach in AML.
What the study was
- Study design
- In vitro and transcriptomic validation study
- Population
- AML patient samples and cell lines
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for Immunotherapy of Cancer
Why it surfaced
High novelty: refutation of a widely-cited false-positive finding about BCMA/CAR-T in AML; saves resources from pursuing an invalid target; JITC is a top-tier immunotherapy journal. In vitro study caps score to max 7.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.